Babies. VZIG (125 ED) should be introduced as soon as possible after giving birth to newborns whose mothers ill wind smallpox within 5 days before or within 2 days after birth. Approximately half of these children can expect the development of wind smallpox. If they need to be hospitalized after 10 days of age, they must be kept in strict isolation until the 21 th day.
For donoshennyh healthy children who were in contact with the wind smallpox two or more days after birth, including those whose mothers have developed a rash later than 48 hours after birth VZIG not shown as unknown, whether exposed to greater risk of complications from the wind smallpox, children, sick with smallpox wind under these conditions than older children. However, due to poor permeability of antibodies through the placenta to rapnye of pregnancy, all children born before 28 weeks gestation or weighing less than 1 kg, who are in need of hospitalization to treat nedonoshennosti or related conditions, and who is in contact with smallpox in the wind, must be VZIG (125 ED). This recommendation nedonoshennym also applies to children born after 28 weeks of pregnancy, whose mothers have in the past has not been rescheduled infection.
Subsequent contacts and monitoring of recipients VZIG. Application VZIG can cause subclinical infection. Testing recipients can be conducted within 2 months or later after VZIG to infection wind smallpox to determine their immune status. However, it is unclear whether a lengthy defense subclinical infection after VZIG. Thus, a patient who has subclinical infection was registered, probably should have VZIG in subsequent recognized contact with the wind smallpox.
Unknown exact duration of protection from wind smallpox posed recipient VZIG. If the second contact occurs in more than three weeks after the application of VZIG recipient, who has not developed chickenpox, another dose of VZIG should be introduced.
Active immunization. Experimental live vaccine against smallpox wind intensively used in healthy children and children with malignant tumors, but are not currently permitted for use in the United States.